Endocrine disorders after combined chemoradiotherapy in Hodgkin Lymphoma survivors

BACKGROUND: Hodgkin’s lymphoma (HL) is one of the most common malignant lymphoproliferative diseases. Chemotherapy and radiotherapy used in the treatment of LH induce a number of toxic effects leading to dysfunction of endocrine system. Hormonal disorders in HL and their relationships with the therapy used remain to be clarified.

AIM: To assess disorders of the endocrine function of thyroid, parathyroid glands and gonads in HL survivors.

MATERIALS AND METHODS: Screening of endocrine dysfunction of the thyroid, parathyroid glands and gonads was performed in 160 adult patients with HL, 55 men and 105 women, at remission stage induced by chemotherapy or chemoradiotherapy. Forty healthy subjects, matched by age, were acted as control. The levels of TSH, T3, free T4, PTH, FSH, LH, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), and sex-hormone binding globulin (SHBG) were measured in blood serum by ELISA. Bone mineral density (BMD) was assessed by DEXA.

RESULTS: Hypothyroidism (25%), hyperparathyroidism (15.6%) and hypogonadism (29% of men and 25.3% of women) were the most prevalent endocrine disorders in LH survivors. Hypothyroidism was significantly more common in patients after chemoradiotherapy than in those who received only chemotherapy (χ2=9.4, р=0.002). In patients with hyperparathyroidism, there were negative correlations between PTH levels and BMD in the lumbar spine (r=-0.74, p=0.00002) and in the femoral neck (r=-0.66, p=0.0003). Men with HL demonstrated lower free testosterone concentrations when compared to control (p=0.04); LH and FSH levels were elevated (p=0.0004 and p=0.04, respectively). In men with HL the levels of DHEA-S were reduced (p=0.0009). The increased SHBG concentrations were revealed in 13 (23.6%) men. Women of reproductive age with HL had higher levels of LH in the luteal phase (p=0.05) and FSH in the follicular phase (p=0.02) than controls.

CONCLUSION: The data indicate a high prevalence of the dysfunctions of thyroid, parathyroid glands, and gonads in HL survivors. Screening for endocrine disorders in these patients is highly recommended.

1. Russian clinical guidelines on diagnosis and treatment of lymphoproliferative disorders. Ed. by IV Poddubnaya, VG Savchenko. Moscow: Buki Vedi Publ.; 2016. (In Russ.).

2. Kaseb H, Babiker H. Cancer, Lymphoma, Hodgkin. StatPearls Publishing: Treasure Island, USA (FL); 2018.

3. Master S, Koshy N, Wilkinson B, et al. Effect of radiation therapy on survival in Hodgkin’s lymphoma: A SEER data analysis. Anticancer Res. 2017;37(6):3035-3043. doi: https://doi.org/10.21873/anticanres.11658

4. Hodgson D. Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: optimizing treatment for individual patients. Clin Adv Hematol Oncol. 2015;13(2):103-112.

5. Golounina OO, Pavlova MG, Belaya ZE, et al. Endocrine late-effects and bone mineral density after combined treatment of malignant brain tumors in childhood and adolescence. Problems of Endocrinology. 2021;67(1):31-40. (In Russ.). doi: https://doi.org/10.14341/probl12680

6. Zenkova EV, Bondar IA, Pospelova TI. Reproductive system state in men with hemoblastosis remission reduction of different stages. Journal of Siberian Medical Sciences. 2010;(6):1-8. (In Russ.).

7. Zvyagintseva DA, Kulyova SA, Tsyrlina EV, Novikov SN. Thyroid dysfunction after radiotherapy in children with Hodgkin’s lymphoma. Oncopediatrics. 2018;5(1):24-31. (In Russ.). doi: https://doi.org/10.24412/Fg-vMdKUAlA

8. Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76(4):699-728. doi: https://doi.org/10.1007/s00018-018-2956-z

9. Witkowska M, Majchrzak A, Smolewski P. The Role of Radiotherapy in Hodgkin’s Lymphoma: What Has Been Achieved during the Last 50 Years? Biomed Res Int. 2015;2015(4):1-8. doi: https://doi.org/10.1155/2015/485071

10. Hartmann K. Thyroid disorders in the oncology patient. J Adv Pract Oncol. 2015;6(2):99-106. doi: https://doi.org/10.6004/jadpro.2015.6.2.2

11. Pinnix C, Cella L, Andraos T, et al. Predictors of hypothyroidism in hodgkin lymphoma survivors after intensity modulated versus 3-dimensional radiation therapy. Int J Radiat Oncol Biol Phys. 2018;101(3):530-540. doi: https://doi.org/10.1016/j.ijrobp.2018.03.003

12. Troshina YA, Abdulkhabirova FM. Euthyroid sick syndrome. Problems of Endocrinology. 2001;47(6):34-36. (In Russ.). doi: https://doi.org/10.14341/probl11738

13. Cusano N, Silverberg S, Bilezikian J. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33-39. doi: https://doi.org/10.1016/j.jocd.2012.12.001

14. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377-386. doi: https://doi.org/10.3322/caac.21489

15. Merza W, Daoud MS, Almothaffar A. Serum magnesium concentration in patients with leukemia and lymphoma. Journal of the Faculty of Medicine, Baghdad. 2008;52(1):101-104. doi: https://doi.org/10.32007/1193%g101-104

16. Oronsky B, Caroen S, Oronsky A, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017; 80(5):895-907. doi: https://doi.org/10.1007/s00280-017-3392-8

17. Hakami Y, Khan A. Hypoparathyroidism. Front Horm Res. 2019;(51):109-126. doi: https://doi.org/10.1159/000491042

18. Miltényi Z, Keresztes K, Lakos G, et al. Is the Treatment of Hodgkin’s Disease Detrimental to the Parathyroid Gland? Acta Haematol. 2004;112(3):148-151. doi: https://doi.org/10.1159/000079726

19. Gini G, Annibali O, Lupasco D, et al. Gonadal function recovery and fertility in women treated with chemo- and/or radiotherapy for Hodgkin’s and Non-Hodgkin lymphoma. Chemotherapy. 2019;64(1):36-41. doi: https://doi.org/10.1159/000499535

20. Poorvu PD, Frazier AL, Feraco AM, et al. Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectr. 2019;3(1):36-41. doi: https://doi.org/10.1093/jncics/pkz008